This new program initiative underscores NIDA's commitment to and interest in supporting epidemiological and HIV prevention research on this understudied and dual risk group. The emphasis is on bridging the gap between the fields of cognitive neuroscience and addiction research. Although participating agencies including CDC and NIJ are collaborators, NIDA is now the lead agency for management and scientific administration. Although violence and victimization within the family were the focus of the RFA, drug and alcohol abuse emerged as a key factor in the predisposing situations. The objective is to enhance collaboration and coordination of all AIDS and AIDS-related investigators at an institution.
Awards are to be made available through both administrative and competing mechanisms.
One of the goals of this announcement is to encourage grantees who have not traditionally focused their research in the AIDS arena to do so. The Medications Development Division has started two clinical trials to provide the data necessary to support NDAs for two products for the treatment of opiate dependence. The first product is a buprenorphine tablet, the second a buprenorphine combined with naloxone tablet. As of January 10, there were 132 subjects enrolled in these studies. The review provided valuable insights for use in developing protocols for potential testing within the Division's clinical program, and for examining compounds currently in various preclinical development stages.